Oramed Pharma (ORMP) Completes ORMD-0901 Phase 1b; No Serious Adverse Events Noted
Tweet Send to a Friend
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced it successfully concluded a Phase Ib study of ORMD-0901, the Company's proprietary oral GLP-1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
